New CDK4/6i data at ASCO reinforce Novartis Kisqali® as only drug in class with ...

Retrieved on: 2022-06-03 16:23:40

Tags for this article:

Chemical compounds

Organic compounds

Protein kinase inhibitors

Astex Pharmaceuticals

Abemaciclib

Letrozole

Novartis AG

Click the tags to see associated articles and topics

New CDK4/6i data at ASCO reinforce Novartis Kisqali® as only drug in class with .... View article details on HISWAI: https://www.novartis.com/news/media-releases/new-cdk46i-data-asco-reinforce-novartis-kisqali-only-drug-class-consistently-proven-overall-survival-benefit-hrher2-metastatic-breast-cancer

Excerpt

These data will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. In a new exploratory analysis of data from the ...

Article found on: www.novartis.com

View Original Article